Using data from the American Heart Association and American Stroke Association Get With The Guidelines–Stroke (GWTG-Stroke) registry, we sought to evaluate the characteristics of patients who experienced a nontraumatic ICH with preceding use of FXa inhibitors compared with no OAC or with warfarin, and to determine the risk of mortality and disability according to the type of anticoagulants, and any incremental risk associated with concomitant antiplatelet therapy in nationwide clinical practice. The gene discussed is F10; the disease is Stroke.